WO1995023972A1 - Heterogeneous immunoassay and its use for detecting proteins - Google Patents

Heterogeneous immunoassay and its use for detecting proteins Download PDF

Info

Publication number
WO1995023972A1
WO1995023972A1 PCT/EP1995/000727 EP9500727W WO9523972A1 WO 1995023972 A1 WO1995023972 A1 WO 1995023972A1 EP 9500727 W EP9500727 W EP 9500727W WO 9523972 A1 WO9523972 A1 WO 9523972A1
Authority
WO
WIPO (PCT)
Prior art keywords
counterpart
partner
heterogeneous immunoassay
heterogeneous
binding
Prior art date
Application number
PCT/EP1995/000727
Other languages
German (de)
French (fr)
Inventor
Martin Reinecke
Thomas Scheper
Wolfgang NOÉ
Original Assignee
Dr. Karl Thomae Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Karl Thomae Gmbh filed Critical Dr. Karl Thomae Gmbh
Priority to AU26074/95A priority Critical patent/AU701926B2/en
Priority to JP7522691A priority patent/JPH09509745A/en
Priority to EP95911276A priority patent/EP0748448A1/en
Publication of WO1995023972A1 publication Critical patent/WO1995023972A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals

Definitions

  • RIAs radioimmunoassays
  • ELISAs enzyme linked immunoassays
  • the present invention is therefore based on the task of developing an immunoassay which meets the following minimum requirements:
  • the measuring system (see FIG. 1) is based on a new heterogeneous immunoassay (heterogeneous elution assay). say) according to the principles of flow injection analysis.
  • a partner of a strong binding reaction is irreversibly immobilized on a solid support, which is preferably implemented in a flow-through cartridge.
  • the unlabeled sample is placed in a buffer stream which is constantly flowing through the system and passed through the immobilizate (see FIG. 2).
  • the binding partner binds its specific counterpart from the sample, while all other substances are discharged through the carrier stream. There is a separation between analytes (counterpart) and interfering substances.
  • the bound substances are then discharged by changing from the carrier buffer to an elution buffer. Washing and conditioning steps can be implemented depending on the analysis problem.
  • the discharged substances are then analyzed with a detector, for example, for their concentration or biological properties. Depending on the detector signal and evaluation method, the concentration of the analyte in the sample can be proportional to the peak integral, for example.
  • the cartridge can be cleaned, conditioned or equilibrated before performing a new sample.
  • the present invention thus relates to a heterogeneous immunoassay, which is characterized in that it contains a partner with a strong binding reaction, the partner being irreversibly immobilized on a solid support and the support in a flowing buffer stream It is possible to expose that the counterpart to be determined and bound, after washing, if necessary, is eluted with a suitable buffer and determined with a detector, its use for the determination of proteins and a method for the determination of proteins below Use of the immunoassay according to the invention.
  • Proteins can be determined (the corresponding antibodies are immobilized in the cartridge), immunoglobulins (through immobilized proteins A / G) or other systems with high binding constants such as avidin / biotin or lectins / glycosylated macromolecules.
  • the sensitivity of the immunoassay can be increased by coupling to fluorescent dyes or other markers before or after the cartridge;
  • the measuring range of the immunoassay can be adjusted by varying the injection volume (cumulative effect), which means that very small concentrations can also be measured;
  • samples can be used directly (i.e. undiluted, not conditioned).
  • concentration of the substance to be analyzed is very large, e.g. B. several milligrams per milliliter, can be adjusted upwards by an increased dispersion of the measuring range;
  • the system can be coupled to an autosampler, which enables simple analysis of several hundred samples in succession; the detection can be carried out in the most varied of ways, the determination of the fluorescence of the proteins or of the UV absorption being particularly suitable;
  • Suitable carriers are the usual carriers such as synthetic or natural polymers or glasses, in particular Sepharos 4B, Eupergit, Eurocell ONB and VA epoxy biosynth, the grain size preferably being between 100 and 200 ⁇ m.
  • the binding of the partner of the desired strong binding reaction to the carrier used can be carried out adsorptively, ionically or covalently, but the latter is preferred.
  • the carrier must be activated for this by customary methods. This can be done by means of hydroxy groups on the support by reaction with bifunctional substances such as glutardialdehyde and subsequent binding of the binding partner, after conversion of the hydroxy groups into amino or carboxy groups and subsequent binding of the binding partner by way of example or by way of example Hydroxide groups occur in groups with terminal epoxy functions and subsequent addition of the binding partner, the latter method being preferred.
  • bifunctional substances such as glutardialdehyde and subsequent binding of the binding partner
  • the system was tested for the following analytes: antithrombin III, rt-PA and antibodies of the IgG type.
  • the first two analytes were tested with poly- and monoclonal antibodies, the IgG antibodies with proteins A and G.
  • Sepharose 4B, Eupergit, Eurocell ONB and VA-Epoxy Biosynth were tested as carriers for the rt-PA assay.
  • Detection was carried out in a flow spectrophotometer (excitation at 273 nm, emission measurement at 340 nm).
  • Figure I shows the calibration line for rt-PA with various immobilizates.
  • Figure II shows the influence of the pH value of the elution solution on the protein fluorescence.
  • Figure III shows the long-term stability for the ATIII measurement: the correlation coefficients are very high, even if the slope of the straight line decreases. A simple two-point calibration per measuring day is sufficient to take this effect into account.
  • Figure IV shows the agreement of the measurement results from two different measurement days after a previous two-point calibration.
  • Figure V shows the agreement of the measurement results of the conventional ELISA's and the measurement values of the automated heterogeneous assay.
  • Figure VI shows that interference from foreign proteins can be excluded by the washing step.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A heterogeneous immunoassay is characterised in that it contains a strongly binding partner irreversibly immobilised on a solid substrate. The substrate may be exposed to a liquid buffer flow so that the bonded non-marked counterpart to be detected be eluted, if required after washing with an appropriate buffer, and detected by a detector. Also disclosed is the use of this heterogeneous immunoassay.

Description

Heterogener Immunassay und dessen Verwendung zur Bestimmung von Proteinen Heterogeneous immunoassay and its use for the determination of proteins
Zur selektiven und sensitiven Bestimmung von Proteinen werden verschiedene Immuntechniken verwendet. Besonders hervorzuhe¬ ben sind die RIAs (Radioimmunassays) oder ELISAs (Enzyme Lin- ked Immunoassays) . Sie werden zur Analyse biotechnologischer Proben standardmäßig verwendet. Auch andere Assays (siehe beispielsweise Freitag, R. ; Scheper, T. ; Spreinat, A. , Antra- nikian, G. (1991b) On-line monitoring of pullulanase produc- tion during continuous culture of Clostridium thermosulfuro- genes . Appl. Microbiol. Biotechnol. 35, 471-476, Freitag, R. ; Scheper, T. ; Schügerl, K. (1991) Development of a turbidime- tric immunoassay for on-line monitoring of proteins in culti- vation processes, Enzyme Microb. Technol . , 13, 969-975, Mat- tiasson, B.; Hakanson H. (1992) Immunochemically based assays for process control, in: Modem Biochemical Engineering (ed. : A. Fiechter) Advances in Biochem. Eng. /Biotechnol. , Vol, 46, Springer Verlag Berlin, pp. : 81-101, Middendorf, C. ; Schulze, B.; Freitag, R. ; Scheper, T.; Howaldt, M. ; Hoffmann, H. (1993) On-line immunoanalysis for bioprocess control, J. Bio¬ technol., 3, 395-403, Miyabayashi, A. ; Mattiasson, B. (1990) A dual Streaming potentiai device used as an affinity sensor for monitoring hybridoma cell cultivation, Anal. Biochem., 184, 165-171 und Stöcklein, W. ; Jäger, V.; Schmid, R.D. (1992) Monitoring of mouse immunoglobulin G by flow injection analytical affinity chromatography, Anal. Chim. Acta, 245(1) , 1-6) können verwendet werden.Various immune techniques are used for the selective and sensitive determination of proteins. The RIAs (radioimmunoassays) or ELISAs (enzyme linked immunoassays) are particularly noteworthy. They are used by default for the analysis of biotechnological samples. Other assays (see, for example, Freitag, R.; Scheper, T.; Spreinat, A., Anranikian, G. (1991b) On-line monitoring of pullulanase production during continuous culture of Clostridium thermosulfurogenes. Appl. Microbiol. Biotechnol. 35, 471-476, Freitag, R.; Scheper, T.; Schügerl, K. (1991) Development of a turbidimetric immunoassay for on-line monitoring of proteins in cultivation processes, Enzyme Microb. Technol., 13, 969-975, Matiasson, B .; Hakanson H. (1992) Immunochemically based assays for process control, in: Modem Biochemical Engineering (ed.: A. Fiechter) Advances in Biochem. Eng. / Biotechnol ., Vol, 46, Springer Verlag Berlin, pp.: 81-101, Middendorf, C.; Schulze, B .; Freitag, R.; Scheper, T .; Howaldt, M.; Hoffmann, H. (1993) On -line immunoanalysis for bioprocess control, J. Bio¬ technol., 3, 395-403, Miyabayashi, A.; Mattiasson, B. (1990) A dual Streaming potentiai device used as an affinity sensor for monitoring hybridoma cell cultivatio n, anal. Biochem., 184, 165-171 and Stöcklein, W.; Jäger, V .; Schmid, R.D. (1992) Monitoring of mouse immunoglobulin G by flow injection analytical affinity chromatography, Anal. Chim. Acta, 245 (1), 1-6) can be used.
Bei einem herkömmlichen ELISA sind verschiedene Schritte nö¬ tig:Various steps are necessary in a conventional ELISA:
Probenverdünnung auf den optimalen Arbeitsbereich, Immunreak¬ tion, Waschschritt und Detektionsschritt. Zwar lassen sich einzelne Schritte automatisieren, doch bleibt der Assay zeitaufwendig, personalintensiv und fehler¬ anfällig. Dies gilt für alle anderen Immunassays auch. Ein anderer Nachteil dieser Assays in Bezug auf die Bioprozeßana¬ lytik ist, daß diese Verfahren alle zur Detektion geringster Proteinmengen ausgelegt sind. Da in Bioprozeßproben höhere Proteinkonzentrationen vorliegen (oberhalb von 1 mg/1) , müs¬ sen deshalb die Proben extrem verdünnt werden, was zusätzlich zeit-, personal- und fehlerintensiv ist.Sample dilution to the optimal working range, immune reaction, washing step and detection step. Individual steps can be automated, but the assay remains time-consuming, personnel-intensive and error-prone. This also applies to all other immunoassays. Another disadvantage of these assays with regard to bioprocess analysis is that these methods are all designed for the detection of very small amounts of protein. Since there are higher protein concentrations in bioprocess samples (above 1 mg / l), the samples must therefore be extremely diluted, which is also time, personnel and error-intensive.
Neben diesen angeführten Punkten fehlen für die Bioprozeßana¬ lytik Verfahren, die schnell, das heißt innerhalb weniger Mi¬ nuten, eine große Anzahl von Proben vermessen und schnell auf andere Fragestellungen umgerüstet werden können, die vollau¬ tomatisch arbeiten und die auch on line am Bioprozeß arbeiten können.In addition to these points, there are no methods for bioprocess analysis that can quickly, ie within a few minutes, measure a large number of samples and quickly convert to other questions that work fully automatically and that also work online on the bioprocess can work.
Neben den oben angeführten reinen Off-line-Verfahren, wurden auch einige automatisierte Verfahren etabliert, beispielswei¬ se seien folgende erwähnt :In addition to the pure off-line processes listed above, some automated processes have also been established, for example the following are mentioned:
- Verfahren über die Detektion von Immunreaktionen mit Hilfe der Strömungspotentialänderung (Miyabayashia und Mattiasson, 1990) , Verfahren zur Trübungsmessung bei der Bildung von Im¬ munkomplexen (turbidimetrischer Assay, TIA) (Freitag et al; 1991a, Middendorf, et al. , 1993) ,- Methods for the detection of immune reactions with the aid of the change in flow potential (Miyabayashia and Mattiasson, 1990), methods for turbidity measurement in the formation of immune complexes (turbidimetric assay, TIA) (Freitag et al; 1991a, Middendorf, et al., 1993) ,
- Verfahren zur Automatisierung heterogener, kompetitiver As¬ says mit anschließender UV-Detektion (Freitag et al . , 1991b; Stöcklein et al. , 1992) und- Process for the automation of heterogeneous, competitive assays with subsequent UV detection (Freitag et al., 1991b; Stöcklein et al., 1992) and
- Verfahren mit einer automatisierten Durchfluß-ELISA-Technik (Mattiasson und Hakanson, 1992) .- Automated flow ELISA technique (Mattiasson and Hakanson, 1992).
Diese Verfahren sind bis auf das TIA-System recht aufwendig, nur mit großem Aufwand zu automatisieren. Das TIA-System ist das einzige, das schon an realen, industriellen Prozesse ein¬ gesetzt wurde und auch validiert wurde. Ein Nachteil ist der hohe Verbrauch an Antikörpern, da für jeden Assay neue Anti¬ körperlösung aufgegeben werden muß. - -. -With the exception of the TIA system, these processes are quite complex and can only be automated with great effort. The TIA system is the only one that has already been used in real industrial processes and has also been validated. A disadvantage is the high consumption of antibodies, since new antibody solutions have to be applied for each assay. - -. -
Allen Systemen isc hierbei ein hoher Anaiytverbrauch gemein¬ sam, allerdings sind die Standzeiten (bis auf TIA) und der Automatisierungsgrad (bis auf TIA) gering. Die Systeme sind kontaminationsanfällig und eine Abtrennung störender Substan¬ zen ist gar nicht oder nur über Verdünnungsschritte möglich. Ohne Verdünnungsschrittε kommt nur der TIA aus.All systems have a high consumption of analysis in common, but the downtimes (except for TIA) and the degree of automation (except for TIA) are low. The systems are susceptible to contamination and a separation of interfering substances is not possible at all or only possible through dilution steps. Only the TIA manages without a dilution step.
Der vorliegenden Erfindung liegt somit die Aufgabε zugrundε, einen Immunassay zu entwickeln, welcher folgende Mindestan¬ forderungen erfüllt:The present invention is therefore based on the task of developing an immunoassay which meets the following minimum requirements:
- allgemeingültiges Analysensystem untεr Ausnutzung von Affi¬ nitätsreaktionen;- General analysis system using affinity reactions;
- Immobilisierung der Affinitätskomponentε zur wiederhoibaren Benutzung, z. B. von mindestens 100 Assays;- Immobilization of the affinity component for repeatable use, e.g. B. of at least 100 assays;
- keine Probenverdünnung notwendig;- no sample dilution necessary;
- einfache Entfernung von Störsubst-anzen;- easy removal of interfering substances;
- vollständig automatisierbar;- fully automated;
- einfach anzupassender Meßbereich;- easy to adjust measuring range;
- keine Gefahr von Kontaminationen;- no risk of contamination;
- variable Detεktionsmöglichkeiten;- variable detection options;
- jεderzeit kalibrierbar;- Can be calibrated at any time;
- Einsatz zur On-line- und Off-line-Analyse (mindestens 10 Proben pro Stunde) ;- Use for on-line and off-line analysis (at least 10 samples per hour);
- einfach umzurüsten;- easy to change over;
- Möglichkeit der Analyse verschiedener IgGs mit einer Immun¬ kartusche (mit immobilisiertem Protein A oder G) .- Possibility of analyzing different IgGs with an immune cartridge (with immobilized protein A or G).
Erfindungsgemäß basiert die Mεßanlage (siehe Figur 1) auf einem neuen hetεrogεnen Immunassay (heterogenεr Elutionsas- say) nach den Prinzipien der Fließinjektionsanalyse. Hierbei wird ein Partner einer starken Bindungsreaktion auf einen festen Träger irreversibel immobilisiert, wobei dieser vor¬ zugsweise in eine Durchflußkartusche implementiert wird. Nach der Immobilisierung des Bindungspartner auf einem geeigneten Trägermaterial wird die nicht markierte Probe in einen stän¬ dig durch das System fließenden Pufferstrom aufgegeben und durch das Immobilisat geführt (siehe Figur 2) . Der Bindungs- partner bindet seinen spezifischen Gegenpart aus der Probe, während alle anderen Stoffe durch den Trägerstrom ausgetragen werden. Es kommt zu einer Trennung zwischen Analyten (Gegen¬ part) und Störsubstanzen. Anschließend werden die gebunden Stoffe durch einen Wechsel von dem Trägerpuffer auf einen Elutionspuffer ausgetragen. Wasch- und Konditionierungs- schritte können je nach Analysenproblem implementiert werden. Die ausgetragenen Stoffe werden dann anschließend mit einem Detektor zum Beispiel auf ihre Konzentration oder biologische Eigenschaften analysiert. Je nach Detektorsignal und Aus- wertemethode kann die Konzentration des Analyten in der Probe zum Beispiel proportional zum Peakintegral sein. Vor einer erneuten Probenaufgaben kann die Kartusche gereinigt, kondi- tioniert oder äquilibriert werden.According to the invention, the measuring system (see FIG. 1) is based on a new heterogeneous immunoassay (heterogeneous elution assay). say) according to the principles of flow injection analysis. Here, a partner of a strong binding reaction is irreversibly immobilized on a solid support, which is preferably implemented in a flow-through cartridge. After the binding partner has been immobilized on a suitable carrier material, the unlabeled sample is placed in a buffer stream which is constantly flowing through the system and passed through the immobilizate (see FIG. 2). The binding partner binds its specific counterpart from the sample, while all other substances are discharged through the carrier stream. There is a separation between analytes (counterpart) and interfering substances. The bound substances are then discharged by changing from the carrier buffer to an elution buffer. Washing and conditioning steps can be implemented depending on the analysis problem. The discharged substances are then analyzed with a detector, for example, for their concentration or biological properties. Depending on the detector signal and evaluation method, the concentration of the analyte in the sample can be proportional to the peak integral, for example. The cartridge can be cleaned, conditioned or equilibrated before performing a new sample.
Gegenstand der vorliegenden Erfindung ist somit ein heteroge¬ ner Immunassay, welcher dadurch gekennzeichnet ist, daß die¬ ser einen Partner mit einer starken Bindungsreaktion enthält, wobei der Partner auf einen festen Träger irreversibel immo¬ bilisiert ist und der Träger einem fließenden Pufferstrom in der Weise aussetzbar ist, daß der zu bestimmende und gebun¬ dene nicht markierte Gegenpart nach gegebenenfalls erforder¬ lichem Waschen mit einem geeigneten Puffer eluiert und mit einem Detektor bestimmt wird, dessen Verwendung zur Bestim¬ mung von Proteinen und ein Verfahren zur Bestimmung von Pro¬ teinen unter Verwendung des erfindungsgemäßen Immunassays .The present invention thus relates to a heterogeneous immunoassay, which is characterized in that it contains a partner with a strong binding reaction, the partner being irreversibly immobilized on a solid support and the support in a flowing buffer stream It is possible to expose that the counterpart to be determined and bound, after washing, if necessary, is eluted with a suitable buffer and determined with a detector, its use for the determination of proteins and a method for the determination of proteins below Use of the immunoassay according to the invention.
Das beschriebene System und Analysenprinzip eignet sich, um Proben in wenigen Minuten zu analysieren. Bestimmt werden können Proteine (dabei werden die entsprechenden Antikörper in der Kartusche immobilisiert) , Immunglobuline (durch immo¬ bilisiertes Proteine A/G) oder andere Systeme mit hohen Bin- dungskonstanten wie Avidin/Biotin oder Lectine/glykosilierte Makromoleküle.The system and analysis principle described is suitable for analyzing samples in a few minutes. Proteins can be determined (the corresponding antibodies are immobilized in the cartridge), immunoglobulins (through immobilized proteins A / G) or other systems with high binding constants such as avidin / biotin or lectins / glycosylated macromolecules.
Der erfindungsgemäße Immunassay weist folgendε Vortεile auf:The immunassay according to the invention has the following advantages:
- Das Gerät arbeitet selbstständig und ist voll automatisier¬ bar;- The device works independently and is fully automatable;
- es können sowohl on line als auch off line Proben analy¬ siert werden;- Both on-line and off-line samples can be analyzed;
- es sind nur kurze Analysenzεitεn, z. B. nur wenige Minuten, nötig;- there are only short analysis times, e.g. B. only a few minutes necessary;
- durch Kopplung an Fluoreszenzfarbstoffε odεr andεre Marker vor oder nach der Kartusche kann diε Empfindlichkeit des Im¬ munassays gesteigert werden;the sensitivity of the immunoassay can be increased by coupling to fluorescent dyes or other markers before or after the cartridge;
- eine Analyse in zellhaltigen Probεn ist möglich;an analysis in cell-containing samples is possible;
- durch eine Optimierung der Ξlutionsbedingungεn kann er¬ reicht werden, daß sowohl in der Kartusche als auch im Fließ- system kein Bewuchs mit Mikroorganismen stattfindet und kεinε weiterεn Rεinigungszyklεn notwendig sind;- By optimizing the elution conditions it can be achieved that in the cartridge as well as in the flow system there is no growth with microorganisms and no further cleaning cycles are necessary;
- der Meßbereich des Immunassays kann durch Variation dεs In¬ jektionsvolumen (kummulativer Effεkt) angεpaßt werden, hier¬ durch können auch sehr kleine Konzentrationen gemessen wer¬ den;the measuring range of the immunoassay can be adjusted by varying the injection volume (cumulative effect), which means that very small concentrations can also be measured;
- bei Verwendung der Meßanlage können Proben direkt (sprich unverdünnt, nicht konditioniert) eingesetzt werden. Ist hier¬ bei die Konzentration des zu analysierεndεn Stoffεs sehr groß, z. B. mehrere Milligramm pro Milliliter, so kann durch eine erhöhte Dispersion dεr Meßberεich nach oben angepaßt werden;- When using the measuring system, samples can be used directly (i.e. undiluted, not conditioned). Here, the concentration of the substance to be analyzed is very large, e.g. B. several milligrams per milliliter, can be adjusted upwards by an increased dispersion of the measuring range;
- die Anlagε läßt sich an einen Autosampier koppeln, dadurch ist eine einfach Analyse von mehreren hundert Proben hinter¬ einander möglich; - die Detεktion kann auf vεrschiεdenste Arten erfolgen, be¬ sonders geεignεt sind die Bestimmung der Fluoreszenz der Pro¬ teine oder der UV-Absorption;the system can be coupled to an autosampler, which enables simple analysis of several hundred samples in succession; the detection can be carried out in the most varied of ways, the determination of the fluorescence of the proteins or of the UV absorption being particularly suitable;
- da es zu εiner Trennung zwischen Störsubstanzen und Analy¬ ten kommt, können auch zuverlässige Analysεn durchgεführt werden, wenn sich die Zusammensεtzung dεr Störsubstanzen än¬ dert, eine Referenzmessungen ist hierbεi nicht notwendig;since there is a separation between interfering substances and analytes, reliable analyzes can also be carried out if the composition of the interfering substances changes; a reference measurement is not necessary here;
- mit Hilfε dieser neuartigen Kombination ist eine kontamina¬ tionsfreie, störungsfreie, automatisierte Analytik möglich, da verschiedenε Spülschrittε eingeschaltet werden können. Das System kann für beliebige Systeme wiedεrholt verwendet wer¬ den.- With the help of this new combination, contamination-free, trouble-free, automated analysis is possible, since different rinsing steps can be switched on. The system can be used repeatedly for any system.
Als Träger kommen hiεrbei die üblichεn Trägεr wiε syntheti¬ sche oder natürliche Polymere oder Gläser, insbesondere Se- pharosε 4B, Eupergit, Eurocell ONB und VA-Epoxy-Biosynth in Betracht, wobei die Korngröße vorzugsweise jeweils zwischen 100 und 200 μm liεgt. Die Bindung des Partners der gewünsch¬ ten starken Bindungsreaktion an den verwendεten Träger kann hierbei adsorptiv, ionisch oder kovalent erfolgen, wobei je¬ doch die letztεre bevorzugt ist .Suitable carriers are the usual carriers such as synthetic or natural polymers or glasses, in particular Sepharos 4B, Eupergit, Eurocell ONB and VA epoxy biosynth, the grain size preferably being between 100 and 200 μm. The binding of the partner of the desired strong binding reaction to the carrier used can be carried out adsorptively, ionically or covalently, but the latter is preferred.
Zur Ausbildung einer kovalenten Bindung muß der Träger hierzu nach üblichen Methodεn aktiviert werden. Dies kann über Hy- droxygruppen am Träger durch Umsεtzung mit bifunktionεllεn Substanzεn wiε beispielswεise Glutardialdehyd und anschlie¬ ßende Bindung des Bindungspartners , nach Umwandlung der Hy- droxygruppεn in Amino- odεr Carboxygruppεn und anschließende Bindung des Bindungspartners beispiεlswεise mittels der Car- bodiimidmεthodε odεr nach Übεrführung dεr Hydroxidgruppen in Gruppen mit terminalεn Expoxidfunktionεn und anschließεndε Addition dεs Bindungspartners geschehen, wobei die letztere Methode bevorzugt ist.To form a covalent bond, the carrier must be activated for this by customary methods. This can be done by means of hydroxy groups on the support by reaction with bifunctional substances such as glutardialdehyde and subsequent binding of the binding partner, after conversion of the hydroxy groups into amino or carboxy groups and subsequent binding of the binding partner by way of example or by way of example Hydroxide groups occur in groups with terminal epoxy functions and subsequent addition of the binding partner, the latter method being preferred.
Das nachfolgende Beispiel soll die Erfindung näher erläutern: - 1 -The following example is intended to explain the invention in more detail: - 1 -
Bf-i.spielBf-i.spiel
Für folgende Analyte wurden das Systεm ausgεtεstet : Anti- thrombin III, rt-PA und Antikörper des IgG-Typs. Die ersten beiden Analyte wurden mit poly- und monoclonalεn Antikörpεrn ausgεtestet, die IgG-Antikörper mit Protein A und G.The system was tested for the following analytes: antithrombin III, rt-PA and antibodies of the IgG type. The first two analytes were tested with poly- and monoclonal antibodies, the IgG antibodies with proteins A and G.
Für den rt-PA Assay wurden Sepharose 4B, Eupergit, Eurocell ONB und VA-Epoxy Biosynth als Träger getestet . Kaliumphos¬ phatpuffer (0,1 M, pH = 7,4) wurde als Träger-, Wasch/Kondi- tioniεrungs- und Äquilibriεrungspuffεr verwendet. Eine Elu- tion war im basischen mit 0,1 M Kaliumphosphatpuffer (pH = 12,3) und im sauren mit Glycinpuffεr (0,1 M, pH 2,0) möglich.Sepharose 4B, Eupergit, Eurocell ONB and VA-Epoxy Biosynth were tested as carriers for the rt-PA assay. Potassium phosphate buffer (0.1 M, pH = 7.4) was used as a carrier, washing / conditioning and equilibration buffer. Elution was possible in basic with 0.1 M potassium phosphate buffer (pH = 12.3) and in acid with glycine buffer (0.1 M, pH 2.0).
Jeweils 20-100 μl Probe wurden injiziεrt (Dauεr 10 sεc) ; dann wurdε 170 see gewaschen und 150 see eluiert und dεtεktiεrt. Nach εinεr Äquilibrierungszeit von 30 see konnte einε nεue Injektion erfolgen.In each case 20-100 μl sample was injected (duration 10 sεc); then 170 see was washed and 150 see eluted and detected. After an equilibration time of 30 seconds, a new injection could be made.
Die Detεktion erfolgte in einem Durchflußspektrophotometer (Anregung bei 273 nm, Emissionsmεssung bei 340 nm) .Detection was carried out in a flow spectrophotometer (excitation at 273 nm, emission measurement at 340 nm).
Abbildung I zeigt die Kalibriergerade für rt-PA mit verschiε- denen Immobilisaten.Figure I shows the calibration line for rt-PA with various immobilizates.
Abbildung II zeigt dεn Einfluß dεs pH-Werts dεr Elutionslö- sung auf die Proteinfluorεszεnz.Figure II shows the influence of the pH value of the elution solution on the protein fluorescence.
Abbildung III zεigt die Langzeitstabilität für die ATIII-Mes¬ sung: Die Korrelationskoeffizientεn sind sehr hoch, auch wenn die Steigung der Geradεn abnimmt. Eine einfache Zweipunktei¬ chung pro Meßtag reicht aus, um diesεn Effekt zu berücksich¬ tigen.Figure III shows the long-term stability for the ATIII measurement: the correlation coefficients are very high, even if the slope of the straight line decreases. A simple two-point calibration per measuring day is sufficient to take this effect into account.
Abbildung IV zeigt diε Übεreinstimmung der Meßergebnisse von zwei vεrschiedenen Mεßtagen nach vorheriger Zweipunktkali- briεrung. Abbildung V zeigt die Übereinstimmung der Meßergebnisse der herkömmlichen ELISA's und den Meßwerten des automatiserten heterogenen Assays.Figure IV shows the agreement of the measurement results from two different measurement days after a previous two-point calibration. Figure V shows the agreement of the measurement results of the conventional ELISA's and the measurement values of the automated heterogeneous assay.
Abbildung VI zeigt, daß Störungen durch Fremdproteine durch den Waschschritt ausgeschlossen werden können. Figure VI shows that interference from foreign proteins can be excluded by the washing step.

Claims

Patentansprüche claims
1.) Heterogεner Immunassay, weicher dadurch gekennzeichnet ist, daß dieser einen Partner mit einer starken Bindungsreak¬ tion enthält, wobei der Partner auf εinεn festen Träger irre¬ versibel immobilisiert ist und der Trägεr einem fließenden Pufferstrom in der Wεise aussetzbar ist, daß der zu bestim¬ mende und gebundene nicht markiertε Gegenpart nach gegebenen¬ falls erforderlichem Waschen mit einem geeignetεn Puffεr elu- iεrt und mit einem Detektor bestimmt wird.1.) Heterogeneous immunoassay, which is characterized in that it contains a partner with a strong binding reaction, the partner being irreversibly immobilized on its solid support and the support being exposed to a flowing buffer stream in such a way that the determining and bound unmarked counterpart after washing, if necessary, eluted with a suitable buffer and determined with a detector.
2.) Heterogener Immunassay gemäß Anspruch 1, dadurch gekεnn- zeichnet, daß der Bindungspartner in einer Kartusche enthal¬ ten ist.2.) Heterogeneous immunoassay according to claim 1, characterized in that the binding partner is contained in a cartridge.
3. ) Hetεrogenεr Immunassay gεmäß den Ansprüchen 1 und 2, da- duch gekεnnzεichnεt, daß der Gegεnpart ein Antikörper oder ein Protein ist.3.) Heterosrogenic immunoassay according to claims 1 and 2, so that the counterpart is an antibody or a protein.
4.) Heterogener Immunassay gemäß den Ansprüchen 1 und 2, da¬ durch gekennzeichnεt, daß der Bindungspartner ein Protein, ein Immunoglobulin oder ein System mit hohen Bindungskonstan¬ ten wie Avidin/Biotin oder εin Lεctin/glycosiliεrtes Makromo¬ lekül ist.4.) Heterogeneous immunoassay according to claims 1 and 2, characterized by the fact that the binding partner is a protein, an immunoglobulin or a system with high binding constants such as avidin / biotin or εin lectin / glycosylated macromolecule.
5. ) Heterogener Immunassay gemäß den Ansprüchen 1 bis 4, da¬ durch gekennzeichnet, daß zur Steigerung der Empfindlichkeit als Gegenpart ein markierter Gegenpart eingesetzt wird.5.) Heterogeneous immunoassay according to claims 1 to 4, characterized in that a marked counterpart is used to increase the sensitivity as counterpart.
6.) Verfahren zur Bestimmung einεs Gεgenparts, dadurch ge¬ kennzeichnet, daß der Gegenpart an einen immobilisierten Partner auf einem festen Träger gebunden wird, dieser nach gegebenenfalls erforderlichem Waschen eluiert und anschlie¬ ßend mit einem Detektor bestimmt wird. 6.) Method for determining a gene part, characterized in that the counterpart is bound to an immobilized partner on a solid support, which is eluted after washing, if necessary, and then determined with a detector.
PCT/EP1995/000727 1994-03-04 1995-02-28 Heterogeneous immunoassay and its use for detecting proteins WO1995023972A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU26074/95A AU701926B2 (en) 1994-03-04 1995-02-28 Heterogeneous immunoassay and the use thereof for detecting proteins
JP7522691A JPH09509745A (en) 1994-03-04 1995-02-28 Heterogeneous immunoassay and its use for detecting proteins
EP95911276A EP0748448A1 (en) 1994-03-04 1995-02-28 Heterogeneous immunoassay and its use for detecting proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4407142.6 1994-03-04
DE19944407142 DE4407142A1 (en) 1994-03-04 1994-03-04 Heterogeneous immunoassay and its use for the determination of proteins

Publications (1)

Publication Number Publication Date
WO1995023972A1 true WO1995023972A1 (en) 1995-09-08

Family

ID=6511805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/000727 WO1995023972A1 (en) 1994-03-04 1995-02-28 Heterogeneous immunoassay and its use for detecting proteins

Country Status (6)

Country Link
EP (1) EP0748448A1 (en)
JP (1) JPH09509745A (en)
AU (1) AU701926B2 (en)
CA (1) CA2184714A1 (en)
DE (1) DE4407142A1 (en)
WO (1) WO1995023972A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10015448A1 (en) * 2000-03-29 2001-10-11 November Ag Molekulare Medizin Detection and quantification of binding between affinity molecules useful in screening for drugs, does not require removal of reaction solution prior to measurement

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0022005A1 (en) * 1979-06-21 1981-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Process for the separation of a proteinic substance starting from a solution containing it upon affinity filtration, and application of the process to enzymatic analyses
EP0196787A1 (en) * 1985-02-28 1986-10-08 Trustees of Boston University Process for detection of aflatoxins
EP0210107A1 (en) * 1985-07-26 1987-01-28 Lyonnaise Des Eaux - Dumez Continuous-flow immunoassay for organic compounds in a circulating fluid, and means therefor
WO1991016116A1 (en) * 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5884869A (en) * 1996-03-18 1999-03-23 Hughes Electronics Corporation Satellite spin vector control with sun sensor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0022005A1 (en) * 1979-06-21 1981-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Process for the separation of a proteinic substance starting from a solution containing it upon affinity filtration, and application of the process to enzymatic analyses
EP0196787A1 (en) * 1985-02-28 1986-10-08 Trustees of Boston University Process for detection of aflatoxins
EP0210107A1 (en) * 1985-07-26 1987-01-28 Lyonnaise Des Eaux - Dumez Continuous-flow immunoassay for organic compounds in a circulating fluid, and means therefor
WO1991016116A1 (en) * 1990-04-23 1991-10-31 Cellpro Incorporated Immunoselection device and method

Also Published As

Publication number Publication date
CA2184714A1 (en) 1995-09-08
AU701926B2 (en) 1999-02-11
AU2607495A (en) 1995-09-18
DE4407142A1 (en) 1995-09-07
EP0748448A1 (en) 1996-12-18
JPH09509745A (en) 1997-09-30

Similar Documents

Publication Publication Date Title
DE3705686C2 (en) Methods for the determination of antibodies
Lenehan et al. Sequential injection analysis
Dill et al. Detection of salmonella in poultry using a silicon chip-based biosensor
DE69817794T2 (en) METHOD FOR DETERMINING THE PERCENTAGE OF GLYCOSILED HEMOGLOBIN
DE4126436C2 (en)
EP1767941A1 (en) Chromatographic detection apparatus, method of testing and kit utilizing the same
EP0407904B1 (en) Method for the determination of an analyte
US5543329A (en) Sensor for antigen-antibody reactions
Puchades et al. Recent developments in flow injection immunoanalysis
US8545773B2 (en) Versatile multichannel capillary biosensor system
Puchades et al. A comprehensive overview on the application of flow injection techniques in immunoanalysis
EP0634015B1 (en) One-way reaction vessel for the solid-phase immunological analysis of, and a method of measuring constituents which can be determined via immune reactions
DE19540098C2 (en) Method and multi-channel biosensor for multi-component analysis of mixtures and / or mixtures
DE10043113A1 (en) Increasing measurement accuracy of sensor, especially biosensor for samples with reagents, by fitting fluorescent standard strip to each sensor and using signal deviations from nominal values as correction values
DE69310537T2 (en) TWO-SIDED IMMUNOASSAY FOR AN ANTIBODY WITH CHEMILUMINESCENT MARKER AND BIOTIN-TIED LIGAND
WO1995023972A1 (en) Heterogeneous immunoassay and its use for detecting proteins
Kessler et al. Nonimmunological assay of urinary albumin based on laser-induced fluorescence
EP0227921A1 (en) Process for the determination of an immunologically bindable substance
Courtais et al. Evaluation of two sirolimus assays using the ARCHITECT-i1000® CMIA or RxL® ACMIA methods in comparison with the IMx® MEIA method
EP1277505B1 (en) Apparatus, method and flux-analysis system for capturing immunogenic particles
DE4216980C2 (en) Immunosensory detection method
DE4214589C2 (en) Immunosensor and measuring method for the quantitative determination of constituents in liquids
EP0707211A1 (en) Reusable solid phase for specific binding reactions
DE4223791C1 (en) Method and device for the detection of analytes in liquids
DE19645569C1 (en) Two-component device for simultaneous immunoassays

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995911276

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2184714

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1995911276

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995911276

Country of ref document: EP